32868-25-0

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(4-aminophenyl)propionate serves as a crucial intermediate in the synthesis of non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen and ibuprofen. Its role in the production of these medications is pivotal due to its ability to contribute to the development of effective treatments for inflammation and pain.
Used as a Building Block in Organic Synthesis:
In the chemical industry, ethyl 2-(4-aminophenyl)propionate is utilized as a building block in the synthesis of various organic compounds and functional materials. Its unique structure allows it to be a key component in creating a wide range of products with different applications.

InChI:InChI=1/C11H15NO2/c1-3-14-11(13)8(2)9-4-6-10(12)7-5-9/h4-8H,3,12H2,1-2H3

Upstream product

• 50712-64-6 ethyl 2-(4-nitrophenyl)propionate 
• 64-17-5 ethanol 
• 59430-62-5 2-(4-aminophenyl)propionic acid 
• 350-46-9 4-Fluoronitrobenzene 
• 67-56-1 methanol 
• 19910-33-9 2-(4-nitrophenyl)propanoic acid 
• 104-03-0 4-nitrobenzeneacetic acid 
• 5445-26-1 ETHYL 4-NITROPHENYLACETATE 
• 36691-05-1 2-(4-phthalimido-phenyl)-propionic acid ethyl ester 
• 36691-06-2 ethyl 2-(4-(1,3-dioxoisoindolin-2-yl)phenyl)acetate 
• 5438-70-0 ethyl (4-amino-3,5-dibromophenyl)acetate 
• 1823-91-2 1-phenylethyl cyanide 
• 50712-63-5 2-(4-nitrophenyl)-propionitrile 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 67266-38-0 2-[4-(1,1-dioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-yl)-phenyl]-propionic acid ethyl ester 
• 86373-89-9 2-{4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-propionic acid ethyl ester 
• 93371-96-1 2-<4-(3-oxo-1,2-benzisotiazolin-2-il)fenil>propionato di etile 
• 118618-32-9 ethyl 2-(p-cyano-phenyl)-propionate 
• 77440-31-4 4-fenil-α-propionato d'etile 
• 81265-53-4 estere etilico dell'acido 2-<4-(2H-indazol-2-il)fenil>propionico 
• 36691-00-6 ethyl 2-(4'-(1-oxo-2-isoindolinyl)phenyl)propionate 
• 367255-31-0 2-(4-hydrazinophenyl) propionic acid ethyl ester 
• 31842-01-0 indoprofen 
• 86373-90-2 2-{4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-propionic acid 
• 50712-61-3 C₂₀H₂₂ClNO₄ 
• 50712-60-2 C₁₉H₂₀ClNO₃ 
• 50712-62-4 C₂₀H₂₂ClNO₃ 
• 60494-59-9 2-(4-aminophenyl)1-propanol 

Relevant academic research and scientific papers

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound shown as a formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Experiments prove that the compound has good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor and drugs for preventing and/or treating IL-17A mediated diseases (such as inflammation, autoimmune diseases, infectious diseases, cancers and precancerous syndromes), and provides a new medical possibility for clinical treatment of diseases related to abnormal IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Preparation method of alminoprofen intermediate

The invention discloses a preparation method of an alminoprofen intermediate, belongs to the field of organic chemical synthesis, and provides a new technical route for improving the defects of synthetic reaction of ethyl 2-(4-amino-phenyl)propionate: 1) taking p-fluoronitrobenzene and diethyl methylmalonate as raw materials, adding alkali, conducting heating, finishing the reaction, conducting cooling, conducting hydrolyzing with alkali, after the reaction is finished, conducting layering, conducting washing with water, extracting impurities, adjusting the pH value, extracting a product, and conducting concentrating to obtain AMLF02; 2) heating AMLF02 in a solvent to 55-75 DEG C, and dropwise adding thionyl chloride for esterification reaction, conducting cooling, adjusting the pH, directly adding a catalyst for reduction at the temperature of 70-80 DEG C, after the reaction is finished, conducting filtering with the aid of diatomite, neutralizing the filtrate to 7-8, conducting concentrating to remove ethanol, extracting a water phase with methylbenzene, and conducting concentrating to obtain AMLF04. The method has the beneficial effects that the problem of slow filtration is solved, extraction is omitted, time is saved, and cost is saved; direct layering is performed after reaction, the amount of hydrochloric acid is reduced, and the treatment difficulty of three wastes is reduced; and safe hydrazine hydrate replaces active nickel.

Application of the mild-condition phthalimidine synthesis with use of 1,2,3-1h-benzotriazole and 2-mercaptoethanol as dual synthetic auxiliaries. Effective synthesis of phthalimidines possessing a variety of substituents at 2-position

The mild-condition phthalimidine synthesis based on Mannich type 1:1 condensation reaction between o-phthalaldehyde with a variety of primary amines in the presence of excess 2-mercaptoethanol and 1,2,3-1H-benzotriazole as "dual synthetic auxiliaries" in MeCN for 13 h at room temperature afford 2-substituted phthalimidines (2,3-dihydroisoindol-1-one) in fair to good isolated yields.

Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 μM) and in vivo antithrombotic efficacy.

Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions

Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

A three-component coupling process based on vicarious nucleophilic substitution (VNSAR)-alkylation reactions: An approach to indoprofen and derivatives

The intermediate anion derived from the vicarious nucleophilic substitution (VNS) of hydrogen reacts with a series of alkyl halides to generate the corresponding α-alkylated conventional VNS product in a one-pot process. This one-pot VNS-alkylation reaction offers a convenient route to a range α-substituted nitrobenzyl phosphine oxides, sulfones, and esters via a three-component coupling reaction. Reactions of α-chloroethyl phenyl sulfone (14) and ethyl 2-chloropropionate (16) with nitrobenzene followed by subsequent addition of an alkylating agent give a series of sulfones and esters bearing an α-aryl quaternary center. The VNS-alkylation protocol has been applied to the synthesis of derivatives of Indoprofen from nitrobenzene using readily available inexpensive starting materials. Indoprofen itself was prepared using the conventional VNS reaction in four steps and 24% overall yield from nitrobenzene.

Application of the phthalimidine synthesis with use of 1,2,3-1 H-benzotriazole and 2-mercaptoethanol as dual synthetic auxiliaries. Part 1. A simple synthesis of (±)-Indoprofen

A representative nonsteroidal anti-inflammatory drug indoprofen is prepared in 4 steps from the commercially available 2-(4-nitrophenyl)propanoic acid. The key step is the mild phthalimidine synthesis by the double Mannich condensation of o-phthalaldehyde with ethyl 2-(4-aminophenyl)propanoate with use of 1,2,3-1H-benzotriazole and 2-mercaptoethanol as dual synthetic auxiliaries.

Immunomodulating agent

Phenylacetic acid derivatives of the formula: STR1 wherein R1 is hydrogen or STR2 wherein R5 is an alkyl group of 1-6 carbon atoms or an aryl group; R2 and R3 are independently hydrogen or an alkyl group of 1-4 carbon atoms; R4 is hydrogen or an alkyl group of 1-4 carbon atoms, have been found to possess immunomodulating activity.

Protection of Primary Amines as N-Substituted 2,5-Dimethylpyrroles

Protection of primary amine group is achieved by incorporating it into an N-substituted 2,5-dimethylpyrrole system.The method affords protection against strong bases and nucleophiles, heating with concentrated alkali, standard mineral acid work-up conditions, and various other reagents.Phenyl-, pyridil-, thiazolyl-, and alkyl-amines have been studied.All give trisubstituted pyrroles in high yield (>80percent) by reaction with hexane-2,5-dione.The pyrroles from the first three types are stable to storage; even the N-alkyl compounds can be used without difficulty.Regeneration of the amine group, by treatment with hydrxylamine hydrochloride, is efficient (80percent yield) with the phenyl, pyridyl, and alkyl compounds but less satisfactory (60 - 65percent generally but down to 25percent in two cases) with the thiazolyl derivatives.